Bio-Techne Corp
TECH Healthcare Biotechnology
Bio-Techne Corp’s revenue for fiscal 2026 (year ended June 2026) was $1.2 billion, roughly unchanged from fiscal 2025. In the quarter to June 2026, revenue grew 1.33%, EPS grew 418.2%, free cash flow fell 6.83% and total debt fell 42.2%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for three consecutive years.
Follow TECH
Bio-Techne Corp (TECH) Revenue
Bio-Techne Corp's revenue for fiscal 2026 was $1.2B, unchanged from fiscal 2025. Over the past ten years it has ranged from $452.2M (fiscal 2015) to $1.2B (fiscal 2025); the current reading is higher than 92% of that period. Bio-Techne Corp ranks 19th of 401 Biotechnology companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2026 | $1.2B | (0.38%) |
| FY2025 | $1.2B | 5.23% |
| FY2024 | $1.2B | 1.97% |
| FY2023 | $1.1B | 2.81% |
| FY2022 | $1.1B | 18.75% |
| FY2021 | $931.0M | 26.04% |
| FY2020 | $738.7M | 3.46% |
| FY2019 | $714.0M | 11.04% |
| FY2018 | $643.0M | 14.21% |
| FY2017 | $563.0M | 12.82% |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Jun 2026 | $321.2M | 3.14% |
| Mar 2026 | $311.4M | 5.25% |
| Dec 2025 | $295.9M | 3.25% |
| Sep 2025 | $286.6M | (9.59%) |
| 42 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| BMRN BioMarin Pharmaceutical Inc. compare | $3.4B |
| MDGL Madrigal Pharmaceuticals, Inc. compare | $1.3B |
| TECH Bio-Techne Corp | $1.2B |
| CORT Corcept Therapeutics Incorporated compare | $830.8M |
| BBIO BridgeBio Pharma, Inc. compare | $713.1M |
| KRYS Krystal Biotech, Inc. compare | $440.5M |
| IBRX ImmunityBio, Inc. compare | $165.8M |
| SMMT Summit Therapeutics PLC compare | $705.0K |
| PCVX Vaxcyte, Inc. compare | — |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on TECH
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement